Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Lindi Chen 1 , Raphaël F. Rousseau 2 , Steven A. Middleton 3 , Gwen L. Nichols 3 , David R. Newell 1 , John Lunec 1 and Deborah A. Tweddle 1 1 Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom 2 Genentech Inc., South San Francisco, CA, USA 3 Hoffmann-La Roche Inc., Nutley, NJ, USA Correspondence to: Deborah A. Tweddle, email: // Keywords : neuroblastoma, MDM2-p53 antagonists, RG7388, combination therapy, Calcusyn Received : December 17, 2014 Accepted : February 17, 2015 Published : March 10, 2015 Abstract Neuroblastoma is a predominantly p53 wild-type (wt) tumour and MDM2-p53 antagonists offer a novel therapeutic strategy for neuroblastoma patients. RG7388 (Roche) is currently undergoing early phase clinical evaluation in adults. This study assessed the efficacy of RG7388 as a single-agent and in combination with chemotherapies currently used to treat neuroblastoma in a panel of neuroblastoma cell lines. RG7388 GI 50 concentrations were determined in 21 p53-wt and mutant neuroblastoma cell lines of varying MYCN , MDM2 and p14 ARF status, together with MYCN-regulatable Tet21N cells. The primary determinant of response was the presence of wt p53, and overall there was a >200-fold difference in RG7388 GI 50 concentrations for p53-wt versus mutant cell lines. Tet21N MYCN+ cells were significantly more sensitive to RG7388 compared with MYCN- cells. Using median-effect analysis in 5 p53-wt neuroblastoma cell lines, selected combinations of RG7388 with cisplatin, doxorubicin, topotecan, temozolomide and busulfan were synergistic. Furthermore, combination treatments led to increased apoptosis, as evident by higher caspase-3/7 activity compared to either agent alone. These data show that RG7388 is highly potent against p53-wt neuroblastoma cells, and strongly supports its further evaluation as a novel therapy for patients with high-risk neuroblastoma and wt p53 to potentially improve survival and/or reduce toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“The importance of p53 in human cancer is emphasised by observations that p53 is mutated in up to half of all malignancies, whilst aberrant upstream or downstream p53 pathways, including MDM2 amplification and p14ARF inactivation are common events in p53 wild-type (wt) cancers [2].”
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · cited 1×
“MI-63 and NDD0005 were synthesised as previously described [36, 37].”
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 3×
“Subsequently, RG7388, a pyrrolidine and second generation MDM2-p53 antagonist from Hoffman-La Roche with enhanced potency, selectivity and bioavailability, and available in both oral and intravenous (IV) formulations has been developed [6].”
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · cited 1×
“The lead cis-imidazoline, RG7112, was subsequently the first of its class to enter clinical trials and despite demonstrating proofof-mechanism in adult MDM2-amplified liposarcoma patients [4], results from several Phase I trials indicated highly variable bioavailability, a poor tolerability to daily oral administratio…”
Self-citationTovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · cited 2×
“Cell cycle arrest was not always accompanied by induction of apoptosis, and overall, a higher concentration of RG7388 was required to induce apoptosis compared to a G1 arrest, consistent with previous observations and the p53 apoptotic threshold in p53 wt tumour cells [17, 28].”
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.
Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261 · cited 1×
“Cell cycle arrest was not always accompanied by induction of apoptosis, and overall, a higher concentration of RG7388 was required to induce apoptosis compared to a G1 arrest, consistent with previous observations and the p53 apoptotic threshold in p53 wt tumour cells [17, 28].”
Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190 · cited 2×
“Acquisition of resistance through de novo mutations following continuous exposure to Nutlin-3 have however been reported in vitro, and may limit the usefulness of MDM2-p53 antagonists as single-agent therapy [12].”
InfluentialActivation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Iancu-Rubin, C., Mosoyan, G., Glenn, K., Gordon, R. E., Nichols, G. L., & Hoffman, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.012 · Cited by 90 · cited 1×
“The lead cis-imidazoline, RG7112, was subsequently the first of its class to enter clinical trials and despite demonstrating proofof-mechanism in adult MDM2-amplified liposarcoma patients [4], results from several Phase I trials indicated highly variable bioavailability, a poor tolerability to daily oral administratio…”
Self-citationHiggins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0460 · Cited by 63 · cited 3×
“gov; NCT01462175; NCT01773408; NCT02098967) [7, 8].”
Cited by
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Durbin, A. D., Zimmerman, M. W., Dharia, N. V., Abraham, B. J., Iniguez, A. B., Weichert-Leahey, N., He, S., Krill-Burger, J. M., Root, D. E., Vazquez, F., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0191-z · Cited by 283
Arnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23409 · Cited by 85
“have demonstrated that the MDM2 antagonist RG7388 works synergistically with chemotherapeutic agents used in neuroblastoma treatment (cisplatin, doxorubicin, topotecan, temozolomide and busulfan) to achieve a stronger apoptosis induction in neuroblastoma cells in vitro [19].”
Development of selective small molecule MDM2 degraders based on nutlin
Wang, B., Wu, S., Liu, J., Yang, K., Xie, H., & Tang, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.046 · Cited by 77
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“Topotecan and doxorubicin, which are topoisomerase inhibitors, synergize with idasanutlin in p53wt neuroblastoma cells [34].”
Influential
Metadata
- Authors
- Chen, L., Rousseau, R. F., Middleton, S. A., Nichols, G. L., Newell, D. R., Lunec, J., & Tweddle, D. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-03-10
- Volume
- 6
- Issue
- 12
- Pages
- 10207-10221
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1895234166
- Cited by
- 81
- References
- 9
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.